Display Settings:

Format

Send to:

Choose Destination
    J Cell Commun Signal. 2009 Mar;3(1):87-88. Epub 2009 Mar 7.

    Trial by CCN2: a standardized test for fibroproliferative disease?

    Source

    Canadian Institutes of Health Research Group in Skeletal Development and Remodeling, Division of Oral Biology and Department of Physiology and Pharmacology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada, N6A 5C1, andrew.leask@schulich.uwo.ca.

    Abstract

    A major issue concerning clinical trials is the availability of standardized assays to evaluate drug efficacy. Ideally, such assays should test the effect of a putative drug on the expression of a biomarker in biological fluids. In a recent study by Kuiper et al. (PLOS One, 3(7): e2675). The relative levels of vascular endothelial growth factor (VEGF) and CCN2 (connective tissue growth factor [CTGF]) were examined in proliferative diabetic retinopathy (PDR). This paper is the subject of this commentary.

    PMID:
    19266315
    [PubMed - as supplied by publisher]
    PMCID:
    PMC2686749
    Free PMC Article

      Supplemental Content

      Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk